Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Roumell Asset Management Further Limits Exposure to Transcept Pharmaceuticals Inc (TSPT)

Roumell Asset Management, run by Jim Roumell, is reducing its exposure to Transcept Pharmaceuticals Inc (NASDAQ:TSPT). In a recent Form 4 filing with the Securities and Exchange Commission, the fund has revealed the sale of 10,490 shares in three transactions at prices between $3.53 and $3.57. As a result, Roumell is left with 2.2 million shares.

Transcept Pharmaceuticals

Roumell Asset Management has been reducing its stake for a while now. Jim Simons, on the other hand, has been buying Transcept Pharmaceuticals Inc (NASDAQ:TSPT). His fund, Renaissance Technologies, has increased its holding by 32% during the third quarter of 2013 and currently owns 108,200 shares reportedly worth $344,000. D. E. Shaw has also been adding to his position, with his fund, D E Shaw, reporting at the end of September ownership of 36,648 shares valued at $117,000. Cliff Asness joined the club only recently and has initiated a position during Q3. AQR Capital Management currently holds 32,715 shares worth approximately $104,000.

Since the start of 2013, Transcept Pharmaceuticals Inc (NASDAQ:TSPT) stock has fallen 21.5% to a current share price of $3.55. With a market cap of approximately $67 million, the company does not pay a dividend and has a beta of 1.59, which makes it a fairly volatile stock. During the third quarter, Transcept registered net revenues of $382,000 and a loss of $0.25 per share.

It is worth noting that another fund invested in Transcept Pharmaceuticals, SC Fundamental Value Fund, L.P., has recently sent a letter to the board of directors requesting a special shareholder meeting. According to the letter, shareholders are to vote on whether the company should consider continuing operation or consider selling itself/commencing liquidation. The meeting is to take place on December 19th.

Disclosure: none

Recommended reading:

Philip Hempleman, Ardsley Partners Initiate Position in Supernus Pharmaceuticals Inc (SUPN)

Carl Icahn Exercises Options and Reiterates Stake in Hologic, Inc. (HOLX)

Hedge Fund News: David Tepper, George Soros & Man Group

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!